MX2023012266A - Un fab anti-tslp con estabilidad mejorada. - Google Patents
Un fab anti-tslp con estabilidad mejorada.Info
- Publication number
- MX2023012266A MX2023012266A MX2023012266A MX2023012266A MX2023012266A MX 2023012266 A MX2023012266 A MX 2023012266A MX 2023012266 A MX2023012266 A MX 2023012266A MX 2023012266 A MX2023012266 A MX 2023012266A MX 2023012266 A MX2023012266 A MX 2023012266A
- Authority
- MX
- Mexico
- Prior art keywords
- fab
- improved stability
- tslp
- tslp fab
- nucleic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169183 | 2021-04-19 | ||
| PCT/EP2022/060236 WO2022223514A1 (en) | 2021-04-19 | 2022-04-19 | An anti-tslp fab with improved stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012266A true MX2023012266A (es) | 2023-10-24 |
Family
ID=75588042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012266A MX2023012266A (es) | 2021-04-19 | 2022-04-19 | Un fab anti-tslp con estabilidad mejorada. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240199730A1 (https=) |
| EP (1) | EP4326767A1 (https=) |
| JP (1) | JP2024516962A (https=) |
| KR (1) | KR20230172508A (https=) |
| CN (1) | CN117222665A (https=) |
| AR (1) | AR125379A1 (https=) |
| AU (1) | AU2022263281A1 (https=) |
| BR (1) | BR112023021587A2 (https=) |
| CA (1) | CA3216894A1 (https=) |
| CL (1) | CL2023003082A1 (https=) |
| CO (1) | CO2023015286A2 (https=) |
| CR (1) | CR20230533A (https=) |
| EC (1) | ECSP23086870A (https=) |
| IL (1) | IL307651A (https=) |
| MX (1) | MX2023012266A (https=) |
| PH (1) | PH12023552762A1 (https=) |
| SA (1) | SA523451188B1 (https=) |
| TW (1) | TW202306982A (https=) |
| WO (1) | WO2022223514A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022551022A1 (en) * | 2019-10-28 | 2023-03-06 | Medimmune Ltd | Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202529811A (zh) | 2024-01-29 | 2025-08-01 | 瑞典商阿斯特捷利康公司 | 胸腺基質淋巴細胞生成素（ｔｓｌｐ）結合片段之組成物及其使用方法 |
| US20260034317A1 (en) | 2024-05-20 | 2026-02-05 | Medimmune Limited | Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001297872B2 (en) | 2000-11-17 | 2006-11-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| KR102666879B1 (ko) * | 2017-04-12 | 2024-05-23 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
| EP4025602A4 (en) * | 2019-09-04 | 2023-12-13 | Biosion, Inc. | TSLP BINDING ANTIBODIES AND USES THEREOF |
| PH12022551022A1 (en) * | 2019-10-28 | 2023-03-06 | Medimmune Ltd | Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof |
-
2022
- 2022-04-19 PH PH1/2023/552762A patent/PH12023552762A1/en unknown
- 2022-04-19 BR BR112023021587A patent/BR112023021587A2/pt unknown
- 2022-04-19 CN CN202280029099.0A patent/CN117222665A/zh active Pending
- 2022-04-19 WO PCT/EP2022/060236 patent/WO2022223514A1/en not_active Ceased
- 2022-04-19 IL IL307651A patent/IL307651A/en unknown
- 2022-04-19 KR KR1020237038201A patent/KR20230172508A/ko active Pending
- 2022-04-19 CR CR20230533A patent/CR20230533A/es unknown
- 2022-04-19 TW TW111114769A patent/TW202306982A/zh unknown
- 2022-04-19 JP JP2023563876A patent/JP2024516962A/ja active Pending
- 2022-04-19 EP EP22724429.0A patent/EP4326767A1/en active Pending
- 2022-04-19 US US18/287,240 patent/US20240199730A1/en active Pending
- 2022-04-19 AU AU2022263281A patent/AU2022263281A1/en active Pending
- 2022-04-19 CA CA3216894A patent/CA3216894A1/en active Pending
- 2022-04-19 AR ARP220101003A patent/AR125379A1/es unknown
- 2022-04-19 MX MX2023012266A patent/MX2023012266A/es unknown
-
2023
- 2023-10-17 CL CL2023003082A patent/CL2023003082A1/es unknown
- 2023-10-18 SA SA523451188A patent/SA523451188B1/ar unknown
- 2023-11-14 CO CONC2023/0015286A patent/CO2023015286A2/es unknown
- 2023-11-16 EC ECSENADI202386870A patent/ECSP23086870A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024516962A (ja) | 2024-04-18 |
| TW202306982A (zh) | 2023-02-16 |
| CL2023003082A1 (es) | 2024-04-19 |
| EP4326767A1 (en) | 2024-02-28 |
| CN117222665A (zh) | 2023-12-12 |
| CO2023015286A2 (es) | 2024-02-05 |
| BR112023021587A2 (pt) | 2023-12-19 |
| SA523451188B1 (ar) | 2025-06-22 |
| KR20230172508A (ko) | 2023-12-22 |
| AR125379A1 (es) | 2023-07-12 |
| CA3216894A1 (en) | 2022-10-27 |
| AU2022263281A9 (en) | 2023-11-16 |
| CR20230533A (es) | 2024-04-05 |
| IL307651A (en) | 2023-12-01 |
| PH12023552762A1 (en) | 2024-04-15 |
| AU2022263281A1 (en) | 2023-11-09 |
| US20240199730A1 (en) | 2024-06-20 |
| ECSP23086870A (es) | 2023-12-29 |
| WO2022223514A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA523451188B1 (ar) | شظية ربط مولد الضد مضادة لـليمفوبويتين الغدة الصعترية ذو ثبات محسن | |
| MX2025003310A (es) | Integracion dirigida de acidos nucleicos | |
| GB2569733A (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
| GB2569734A (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
| MY201637A (en) | Natural killer cells and ilc3 cells and uses thereof | |
| MX2022003908A (es) | Enzimas y aplicaciones de las mismas. | |
| PH12019502331A1 (en) | Treatment of asthma with anti-tslp antibody | |
| MX2016001317A (es) | Variantes de enzimas. | |
| SA521422495B1 (ar) | مستضدات البروستاتا المستحدثة واستخداماتها | |
| AR100606A1 (es) | Variantes de lipasas y polinucleótidos que las codifican | |
| EA202190736A1 (ru) | Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью | |
| MX2022000425A (es) | Metodos y composiciones que comprenden un nivel reducido de proteinas de celulas hospedadoras. | |
| MX2022010514A (es) | Metodos de secuenciacion de biopolimeros. | |
| WO2016168214A3 (en) | Immunogenic fusion proteins for the treatment of cancer | |
| MD20160014A2 (ro) | Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia | |
| MY187334A (en) | Xylanase | |
| WO2015048523A3 (en) | Mutant chondroitinase abc i compositions and methods of their use | |
| ZA202001019B (en) | Transient silencing of argonaute1 and argonaute4 to increase recombinant protein expression in plants | |
| WO2020185775A3 (en) | Materials and methods for reducing nucleic acid degradation in bacteria | |
| TW201613622A (en) | Composition for skincare and pharmaceutical composition and preparation method thereof | |
| AR104231A1 (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer |